Diabetes 50:2611-2618, 2001
© 2001 by the American Diabetes Association, Inc.
Insulin Therapy Improves Insulin-Stimulated Endothelial Function in Patients With Type 2 Diabetes and Ischemic Heart Disease
Christian Rask-Madsen1,
Nikolaj Ihlemann1,
Thure Krarup2,
Erik Christiansen3,
Lars Kober4,
Caroline Nervil Kistorp5, and
Christian Torp-Pedersen1
1 Department of Cardiology P, Gentofte University Hospital, Copenhagen, Denmark
2 Department of Medicine F, Gentofte University Hospital, Copenhagen, Denmark
3 Department of Endocrinology, Herlev University Hospital, Copenhagen, Denmark
4 Rigshospitalet Heart Center, Copenhagen, Denmark
5 Department of Cardiology and Endocrinology E, Frederiksberg University Hospital, Copenhagen, Denmark
Blunted insulin-stimulated endothelial function may be a mechanism for the development of atherothrombotic disease in type 2 diabetes, but it is unknown whether hypoglycemic drug therapy can modulate this abnormality. We studied patients with type 2 diabetes and stable ischemic heart disease (n = 28) and lean, healthy control subjects (n = 31). Forearm blood flow was measured by venous occlusion plethysmography during dose-response studies of acetylcholine (ACh) and sodium nitroprusside (SNP) infused into the brachial artery. In the patients and 10 healthy control subjects, ACh was repeated after intrabrachial infusion of insulin. Patients were restudied after 2 months of insulin therapy with four daily subcutaneous injections (treatment group, n = 19) or without hypoglycemic drug therapy (time control group, n = 9). Insulin infusion raised venous serum insulin in the forearm to high physiological levels (133 ± 14.6 mU/l in patients) with a minor increase in systemic venous serum insulin. This increased the ACh response by 149 ± 47, 110 ± 33, 100 ± 45, and 106 ± 44% during the four ACh doses in healthy control subjects (P < 0.0001) but had no effect in patients (P = 0.3). After 2 months, HbA1c in the treatment group had decreased from 10.0 ± 0.4 to 7.5 ± 0.2%. Although neither the ACh response (P = 0.09) nor the SNP response (P = 0.4) had changed significantly, insulin stimulation had a significant effect, as the ACh response increased by 58 ± 25, 84 ± 66, 120 ± 93, and 69 ± 36% (P = 0.0002). In the time control group, insulin stimulation remained without effect after 8 weeks (P = 0.7). In conclusion, insulin therapy partly restores insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon
Cardiovascular Actions of Insulin
Endocr. Rev.,
August 1, 2007;
28(5):
463 - 491.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. S. Hermann, W. Li, H. Dominguez, N. Ihlemann, C. Rask-Madsen, A. Major-Pedersen, D. B. Nielsen, K. W. Hansen, M. Hawkins, L. Kober, et al.
Quinapril Treatment Increases Insulin-Stimulated Endothelial Function and Adiponectin Gene Expression in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab.,
March 1, 2006;
91(3):
1001 - 1008.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Lautamaki, K.E. J. Airaksinen, M. Seppanen, J. Toikka, R. Harkonen, M. Luotolahti, R. Borra, J. Sundell, J. Knuuti, and P. Nuutila
Insulin Improves Myocardial Blood Flow in Patients With Type 2 Diabetes and Coronary Artery Disease
Diabetes,
February 1, 2006;
55(2):
511 - 516.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H von Bibra, A Hansen, V Dounis, T Bystedt, K Malmberg, and L Ryden
Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes
Heart,
December 1, 2004;
90(12):
1483 - 1484.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Pistrosch, J. Passauer, S. Fischer, K. Fuecker, M. Hanefeld, and P. Gross
In Type 2 Diabetes, Rosiglitazone Therapy for Insulin Resistance Ameliorates Endothelial Dysfunction Independent of Glucose Control
Diabetes Care,
February 1, 2004;
27(2):
484 - 490.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Clement, S. S. Braithwaite, M. F. Magee, A. Ahmann, E. P. Smith, R. G. Schafer, and I. B. Hirsch
Management of Diabetes and Hyperglycemia in Hospitals
Diabetes Care,
February 1, 2004;
27(2):
553 - 591.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Westerbacka, R. Bergholm, M. Tiikkainen, and H. Yki-Jarvinen
Glargine and Regular Human Insulin Similarly Acutely Enhance Endothelium-Dependent Vasodilatation in Normal Subjects
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2004;
24(2):
320 - 324.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S. Vehkavaara and H. Yki-Jarvinen
3.5 Years of Insulin Therapy With Insulin Glargine Improves In Vivo Endothelial Function in Type 2 Diabetes
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2004;
24(2):
325 - 330.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
C. Rask-Madsen, H. Dominguez, N. Ihlemann, T. Hermann, L. Kober, and C. Torp-Pedersen
Tumor Necrosis Factor-{alpha} Inhibits Insulin's Stimulating Effect on Glucose Uptake and Endothelium-Dependent Vasodilation in Humans
Circulation,
October 14, 2003;
108(15):
1815 - 1821.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Torp-Pedersen, C. Rask-Madsen, I. Gustafsson, F. Gustafsson, and L. Kober
Diabetes mellitus and cardiovascular risk: just another risk factor?
Eur. Heart J. Suppl.,
August 1, 2003;
5(suppl_F):
F26 - F32.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
T. S. Hermann, C. Rask-Madsen, N. Ihlemann, H. Dominguez, C. B. Jensen, H. Storgaard, A. A. Vaag, L. Kober, and C. Torp-Pedersen
Normal Insulin-Stimulated Endothelial Function and Impaired Insulin-Stimulated Muscle Glucose Uptake in Young Adults with Low Birth Weight
J. Clin. Endocrinol. Metab.,
March 1, 2003;
88(3):
1252 - 1257.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Diabetes Association.
|
|
| |
|